Pathophysiological Explorations of Red Blood Cells

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03541525

Acronym

GR-Ex

Enrollment

3750

Registered

2018-05-30

Start date

2017-10-16

Completion date

2037-10-15

Last updated

2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Red Blood Cell Disorder

Brief summary

GR-Ex is a program labelled by Labex (Laboratory of Excellence) by the French Ministry of Higher Education and Research. This program aims to develop the means to improve knowledge in the physiology and pathologies of erythropoiesis, red blood cells and iron metabolism, and to develop new therapeutic protocols capable of providing added value in terms of innovation.

Interventions

OTHERBiological sampling

Biological samples including blood, surgical remainder, urine,...

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* To be affected or have a family history of disease bound to the red blood cell, * For adult subjects, have signed an informed consent form, * For minor or major under legal safeguard subjects, the form must be signed by both parents (for minors) or by the legal representative, * Be affiliated to health insurance.

Exclusion criteria

* Being deprived of freedom

Design outcomes

Primary

Measure	Time frame	Description
Innovative markers of spleen fonctionality	20 years	Retention rate (%) of red blood cells using Microsphiltration compared with non affected subjects
Quantification of inflammation in sickle cell disease	20 years	Activation rate of circulating mastocytes (%)
Markers of post-artesunate hemolysis	20 years	Concentration of pitted red blood cells at day 3
Correlation between transfusion yield and the storage of red blood cell bags	20 years	Increasing in haemoglobin concentration at 6 hours post transfusion
Efficiency of Phosphodiesterase inhibitor on neutrophil adhesion in Sickle cell disease	20 years	Proportional change in adhesion rate (%) of neutrophils measured in the peripheral blood before and after treatment with phosphodiesterase inhibitors
Quantification of mitochondria removal during erythropoiesis in SDC patients, consequences on the mature RBC	20 years	Mitochondria rate and level of ROS in RBC measured by Flow Cytometry
Study of iron metabolism in Diamond-Blackfan Anemia patients	20 years	Dosage of iron metabolism parameters

Countries

Benin, France, Guadeloupe

Contacts

CONTACTSandra Manceau, PhD

sandra.manceau@aphp.fr+33171196435

CONTACTPierre Buffet, MD

pabuffet@gmail.com+33142754456

STUDY_DIRECTOROlivier Hermine, MD, PhD

Assistance Publique - Hôpitaux de Paris

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 10, 2026